REGENERON PHARMACEUTICALS, INC. Other Non-current Assets 2009-2026 | REGN
Beta
What is REGENERON PHARMACEUTICALS, INC.'s current other non-current assets?
REGENERON PHARMACEUTICALS, INC. (REGN) annual other non-current assets for 2025 was $1.82B, a 60.32% increase from 2024. REGENERON PHARMACEUTICALS, INC. other non-current assets for the quarter ending March 31, 2026 was $2.13B.
What was REGENERON PHARMACEUTICALS, INC.'s other non-current assets in 2024?
REGENERON PHARMACEUTICALS, INC. annual other non-current assets for 2024 was $1.14B, a 155.80% increase from 2023.
What was REGENERON PHARMACEUTICALS, INC.'s other non-current assets in 2023?
REGENERON PHARMACEUTICALS, INC. annual other non-current assets for 2023 was $444.1M, a 32.02% increase from 2022.
What is REGENERON PHARMACEUTICALS, INC.'s 5-year other non-current assets CAGR?
REGENERON PHARMACEUTICALS, INC. other non-current assets grew at a compound annual growth rate (CAGR) of 61.05% from FY2020 to FY2025, going from $168.1M to $1.82B over 5 years.
Other Non-current Assets History
Year-over-year comparison from 10-K annual reports
Key Statistics
Trend Direction
Growing
CAGR+61.0%
FY2020
$168.1M
→
FY2025
$1.82B
0910111213141516171819202122232425
5 years selected
Other Non-current Assets History
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $1.82B | +60.3% | 10-K |
| FY2024 | $1.14B | +155.8% | 10-K |
| FY2023 | $444.1M | +32.0% | 10-K |
| FY2022 | $336.4M | +55.7% | 10-K |
| FY2021 | $216.1M | +28.6% | 10-K |
| FY2020 | $168.1M | +16.2% | 10-K |
| FY2019 | $144.7M | +13.6% | 10-K |
| FY2018 | $127.4M | +63.5% | 10-K |
| FY2017 | $77.9M | +283.9% | 10-K |
| FY2016 | $20.3M | +249.3% | 10-K |
| FY2015 | $5.8M | +91.5% | 10-K |
| FY2014 | $3.0M | -43.0% | 10-K |
| FY2013 | $5.3M | -76.9% | 10-K |
| FY2012 | $23.1M | +270.0% | 10-K |
| FY2011 | $6.2M | -8.0% | 10-K |
| FY2010 | $6.8M | -7.5% | 10-K |
| FY2009 | $7.3M | - | 10-K |
Company: REGENERON PHARMACEUTICALS, INC.Ticker: REGNSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →